The Influence of GBA and LRRK2 on Mood Disorders in Parkinson's Disease.

Autor: DeBroff J; Sackler School of Medicine Tel-Aviv University., Omer N; Sackler School of Medicine Tel-Aviv University.; Movement Disorders Unit Neurological Institute, Tel-Aviv Medical Center.; Laboratory of Early Markers of Neurodegeneration Neurological Institute, Tel-Aviv Medical Center., Cohen B; Laboratory of Early Markers of Neurodegeneration Neurological Institute, Tel-Aviv Medical Center., Giladi N; Sackler School of Medicine Tel-Aviv University.; Movement Disorders Unit Neurological Institute, Tel-Aviv Medical Center.; Sagol School of Neuroscience Tel-Aviv University., Kestenbaum M; Sackler School of Medicine Tel-Aviv University.; Neurology department Meir Hospital Kfar-Saba Israel., Shirvan JC; Biogen Inc. Cambridge MA USA., Cedarbaum JM; Biogen Inc. Cambridge MA USA.; Coeruleus Clinical Sciences LLC Woodbridge CT USA., Gana-Weisz M; Genomic Research Laboratory for Neurodegeneration Tel-Aviv Medical Center Tel-Aviv Israel., Goldstein O; Genomic Research Laboratory for Neurodegeneration Tel-Aviv Medical Center Tel-Aviv Israel., Orr-Urtreger A; Sackler School of Medicine Tel-Aviv University.; Sagol School of Neuroscience Tel-Aviv University.; Genomic Research Laboratory for Neurodegeneration Tel-Aviv Medical Center Tel-Aviv Israel., Mirelman A; Sackler School of Medicine Tel-Aviv University.; Laboratory of Early Markers of Neurodegeneration Neurological Institute, Tel-Aviv Medical Center.; Sagol School of Neuroscience Tel-Aviv University., Thaler A; Sackler School of Medicine Tel-Aviv University.; Movement Disorders Unit Neurological Institute, Tel-Aviv Medical Center.; Laboratory of Early Markers of Neurodegeneration Neurological Institute, Tel-Aviv Medical Center.; Sagol School of Neuroscience Tel-Aviv University.
Jazyk: angličtina
Zdroj: Movement disorders clinical practice [Mov Disord Clin Pract] 2023 Mar 21; Vol. 10 (4), pp. 606-616. Date of Electronic Publication: 2023 Mar 21 (Print Publication: 2023).
DOI: 10.1002/mdc3.13722
Abstrakt: Background: Mood disorders have emerged as major non-motor comorbidities in Parkinson's disease (PD) even at the prodromal stage of the disease. Mutations in the LRRK2 and GBA genes are common among Ashkenazi Jews, with more severe phenotype reported for GBA -PD.
Objective: To explore the association between genetic status and mood related disorders before and after diagnosis of PD and the association between mood-related medications, phenotype, and genetic status.
Methods: Participants were genotyped for mutations in the LRRK2 and GBA genes. State of depression, anxiety and non-motor features were evaluated using validated questionnaires. History of mood disorders prior to diagnosis of PD and use of mood-related medications were assessed.
Results: The study included 105 idiopathic PD (iPD), 55 LRRK2 -PD and 94 GBA -PD. Scores on mood related questionnaires and frequency of depression and anxiety before diagnosis were similar between the groups ( p >0.05). However, more GBA -PD patients used mood related medications before PD diagnosis than LRRK2 -PD and iPD (16.5% vs 7.1% and 8.2%, p =0.044). LRRK2 -PD and GBA -PD receiving mood-related medications at time of assessment had worse motor and non-motor phenotype compared to those that did not ( p <0.05). LRRK2 -PD receiving mood related-medications at time of assessment, scored higher on mood-related questionnaires compared to LRRK2 -PD not receiving such medications ( p <0.04).
Conclusions: Prodromal GBA -PD are more frequently treated with mood related-medications despite equal rates of reported mood-related disorders, while LRRK2 -PD with mood-related disorders experience high rates of anxiety and depression despite treatment, attesting to the need of more precise assessment and treatment of these genetic subgroups.
(© 2023 International Parkinson and Movement Disorder Society.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje